Kyntra Bio’s (KYNB) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Kyntra Bio (NASDAQ:KYNB) in a research note issued to investors on Tuesday morning,Benzinga reports. The firm currently has a $43.00 price target on the stock.

Other equities research analysts have also recently issued research reports about the stock. Oppenheimer assumed coverage on shares of Kyntra Bio in a research report on Monday, July 6th. They issued an “outperform” rating and a $35.00 price objective for the company. Weiss Ratings upgraded shares of Kyntra Bio from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, August 14th. Finally, Rodman & Renshaw started coverage on shares of Kyntra Bio in a research report on Tuesday, June 9th. They set a “buy” rating and a $30.00 target price on the stock. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Kyntra Bio has an average rating of “Hold” and a consensus target price of $36.00.

Kyntra Bio Stock Down 0.5%

Kyntra Bio stock opened at $8.49 on Tuesday. The stock has a 50-day simple moving average of $7.35 and a 200 day simple moving average of $7.15. Kyntra Bio has a 12-month low of $6.32 and a 12-month high of $12.58. The stock has a market capitalization of $34.38 million, a price-to-earnings ratio of 0.19 and a beta of 1.06.

Hedge Funds Weigh In On Kyntra Bio

A hedge fund recently bought a new stake in Kyntra Bio stock. Renaissance Technologies LLC purchased a new stake in Kyntra Bio Inc (NASDAQ:KYNB) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 27,481 shares of the company’s stock, valued at approximately $186,000. Renaissance Technologies LLC owned about 0.68% of Kyntra Bio as of its most recent SEC filing. Institutional investors own 72.71% of the company’s stock.

Kyntra Bio Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.